7 Result(s)
within
Medicine & Public Health
Medicine/Public Health, general
Jorge Cortes
Article
-
Article
Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?
-
Article
Open AccessDose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Ponatinib, the only approved all known-BCR::ABL1 inhibitor, is a third-generation tyrosine-kinase inhibitor (TKI) designed to inhibit BCR::ABL1 with or without any single resistance mutation, including T315I, ...
-
Article
Open AccessPredictive models for health outcomes due to SARS-CoV-2, including the effect of vaccination: a systematic review
The interaction between modelers and policymakers is becoming more common due to the increase in computing speed seen in recent decades. The recent pandemic caused by the SARS-CoV-2 virus was no exception. Thu...
-
Article
Open AccessSafety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study
Talacotuzumab, a humanized anti-CD123 monoclonal antibody, was evaluated in combination with decitabine in elderly patients with acute myeloid leukemia (AML) not eligible for intensive chemotherapy. A multicen...
-
Article
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
Outcomes for patients with chronic myeloid leukemia (CML) have substantially improved due to advances in drug development and rational treatment intervention strategies. Despite these significant advances ther...
-
Article
Response kinetics and factors predicting survival in core-binding factor leukemia
-
Article
Imatinib and beyond—exploring the full potential of targeted therapy for CML
Imatinib is the standard frontline therapy for patients with chronic myeloid leukemia (CML); however, a substantial number require alternative therapy owing to imatinib intolerance or imatinib resistance. Stud...
